IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced results from an expanded cohort of 700 patients from the ALIGN-AR pivotal trial for the Trilogy THV System in high-risk patients with symptomatic, severe aortic regurgitation (AR). These results were published in The Lancet and simultaneously presented as part of the Late-Breaking Clinical Trial sessions at PCR London Valves.

IRVINE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the completion of its 1,000th commercial Trilogy procedure, performed in Cologne, Germany, marking a major milestone demonstrating the platform’s growing adoption in treating patients with symptomatic, severe aortic regurgitation (AR) who previously had limited treatment options.

IRVINE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in San Francisco, CA with a live case broadcast from the ARTIST study as well as late-breaking data from PREVUE-VALVE.

IRVINE, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the newly published guidelines from the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) include transcatheter aortic valve implantation (TAVI) as a treatment option for patients with severe, symptomatic aortic regurgitation (AR) when ineligible for surgery. This decision marks the first formal recommendation for TAVI in AR guidelines.

IRVINE, Calif., July 14, 2025 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that patient enrollment has begun in the ARTIST study, an RCT evaluating the safety and effectiveness of the Trilogy System compared to surgical aortic valve replacement (SAVR) in patients with AR. The study is now enrolling patients in both transcatheter and surgical arms with the first case being performed in Los Angeles, California at Cedars-Sinai Medical Center.

IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from PCR London Valves 2023, a leading, annual global valve conference. The Trilogy THV system was featured in multiple case presentations and scientific sessions throughout […]